SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

01 Feb 2023 Evaluate
The revenue zoomed 8.20% to Rs. 8748.90 millions for the quarter ended December 2022 as compared to Rs. 8085.80 millions during the corresponding quarter last year.The Company to register a -36.34%  fall in the net profit for the quarter ended December 2022.Operating Profit reported a sharp decline to 1899.20 millions from 2657.70 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 8748.90 8085.80 8.20 25624.10 23750.10 7.89 31406.40 27185.90 15.52
Other Income 305.10 279.00 9.35 1443.00 1113.10 29.64 1397.30 1035.70 34.91
PBIDT 1899.20 2657.70 -28.54 6507.50 8150.50 -20.16 10306.20 10204.80 0.99
Interest 26.80 7.00 282.86 40.20 19.40 107.22 91.20 69.00 32.17
PBDT 1872.40 2650.70 -29.36 6467.30 8131.10 -20.46 10215.00 10135.80 0.78
Depreciation 322.90 307.10 5.14 948.40 908.70 4.37 1209.60 1114.90 8.49
PBT 1549.50 2343.60 -33.88 5518.90 7222.40 -23.59 9005.40 9020.90 -0.17
TAX 309.90 396.50 -21.84 1103.80 1372.20 -19.56 1806.80 2264.50 -20.21
Deferred Tax 134.60 66.60 102.10 55.20 130.00 -57.54 95.10 97.70 -2.66
PAT 1239.60 1947.10 -36.34 4415.10 5850.20 -24.53 7198.60 6756.40 6.54
Equity 257.10 173.90 47.84 257.10 173.90 47.84 171.70 173.90 -1.27
PBIDTM(%) 21.71 32.87 -33.96 25.40 34.32 -26.00 32.82 37.54 -12.58

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×